Shield Therapeutics PLC (STX)
Market Closed
10 Jan, 15:30
LSE 
£
2. 50
-0.12
-4.76%
£
37.54M Market Cap
- P/E Ratio
0% Div Yield
2,339,265 Volume
0 Eps
£ 2.62
Previous Close Day Range
2.49 2.65
Year Range
1.06 7.8
Summary
STX closed Friday lower at £2.5, a decrease of 4.76% from Thursday's close, completing a monthly decrease of -5.66% or £0.15. Over the past 12 months, STX stock lost -5.66%.
STX is not paying dividends to its shareholders.
The last earnings report, released on Sep 26, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBP).
Want to track STX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
STX Chart
FAQ
What Is the Shield Therapeutics PLC(STX) Stock Price Today?
The STX stock price today is £2.50.
What Stock Exchange Does Shield Therapeutics PLC Trade On?
Shield Therapeutics PLC is listed and trades on the XFRA.
What Is the Stock Symbol for Shield Therapeutics PLC?
The stock symbol for Shield Therapeutics PLC is "STX".
Does Shield Therapeutics PLC Pay Dividends? What's The Current Dividend Yield?
STX is not paying dividends to its shareholders.
What Is the Shield Therapeutics PLC Market Cap?
As of today, Shield Therapeutics PLC market cap is 37.54M.
Did Shield Therapeutics PLC had any splits?
No, Shield Therapeutics PLC has never had a stock split.
Shield Therapeutics PLC Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Anders Lundstrom CEO | LSE Exchange | GB00BYV81293 ISIN |
| United Kingdom Country | 73 Employees | - Last Dividend | - Last Split | - IPO Date |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Contact Information
Address: Northern Design Centre
Phone: 44 1915 118 500
Website: https://www.shieldtherapeutics.com
2025 © Marketlog. All Rights Reserved.
